Jan. 10, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation. This advancement offers

FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated unprecedented potency and durable anti-tumor activity in vitro and in vivo at low doses. IND anticipated in 2H 2025 Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARP8 was confirmed In the MAD-2 trial, RAP-219 was observed to be generally well tolerated with faster titration and higher exposures than in the initial MAD trial Data underscore the potential broad therapeutic index of RAP-219 and dosing flexibility Ongoing Phase 2a trial of RAP-2

1. 恒瑞医药抗PCSK9单抗获批上市 1月10日，NMPA官网最新公示，批准恒瑞医药的注射用瑞卡西单抗上市。瑞卡西单抗是一款抗PCSK9单抗。适应症为：在控制饮食的基础上，与他汀类药物、或者与他汀类药物及其它降脂疗法联合用药，用于接受中等或以上剂量他汀类药物治疗仍无法达到低密度脂蛋白胆固醇(LDL-C)目标的原发性高胆固醇血症（包括杂合子型家族性和非家族性高胆固醇血症)和混合型血脂异常的成人患者；或单药用于非家族性高胆固醇血症和混合型血脂异常的成人患者，以降低低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、载脂蛋白B（ApoB)水平。本次获批的上市申请是基于3项多中心、随机、双盲、安慰剂平行对照的3期临床研究（SHR-1209-301/302/303）。 2. 石药集团糖尿病1类新药获批上市 1月10日，NMPA官网最新公示，石药集团的新型口服DPP-4抑制剂普卢格列汀片已在中国获批上市，该药适用于改善成人2型糖尿病患者的血糖控制。普卢格列汀片的上市得到了两项3期临床试验的支持。这两项试验共入组约1000例2型糖尿病受试者，以评估普卢格列汀片单药及联合二甲双胍用于2型糖尿病治疗的

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS OBDS is an alternative delivery method designed to improve the patient experience and currently avail

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IND-enablement of bispecifics Lead program is a phase 2-ready, long-acting anti-TSLP monoclonal antibody with potential to be first-to-market with dosing every 6 months Building a discovery pipeline of long-acting bispecifics harnessing validated targets and syn

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia, with no radiographic evidence of rickets – - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; on track to complete dosing in January 2026, with topline data to follow in early 2026 – - Regulatory gu

肝硬化是一种以肝组织纤维化和功能紊乱为特征的严重慢性肝病，是全球范围内导致死亡和病痛的重要原因。据统计，每年因肝病引发的死亡人数高达200万，占全球死亡总数的4%。在肝硬化的晚期阶段，患者常因腹水、食管静脉曲张破裂出血和肝性脑病等并发症陷入生命危机。而唯一能够有效治愈晚期肝硬化的治疗手段是肝移植，但受限于供体器官短缺和手术复杂性，肝移植的应用范围极其有限。因此，寻找替代性疗法成为肝病研究的热点。 近年来，细胞疗法为肝硬化的治疗提供了新希望。其中，通过骨髓来源的巨噬细胞（macrophages）注射，不仅能减少炎症，还能促进纤维化的逆转和肝组织再生，显示出显著的潜在疗效。1月8日Nature Medicine的研究报道“Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial”，探讨了自体单核细胞来源巨噬细胞（autologous monocyte-derived macrophages）疗法在代偿期肝硬化患者中的安全性和初步疗效。 这项多中心

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development Jan. 09, 2025 -- Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today the closing of an oversubscribed CHF 50 million (approx

VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis pigmentosa FDA Rare Pediatric Disease Designation qualifies ViGeneron for potential eligibility for a Priority Review Voucher (PRV) upon marketing approval The independent Data Safety Monitoring Board (DSMB) unanimously approved dose escalation in VG901’s ongoing Phase 1b clinical trial Jan. 08, 2025 -- Vi